From June 25 to 27, 2024, Dr. Jiasheng Song, founder of DIFF Biotech, was invited to attend the 2024 U.S.-China Collaborative Innovation Project Promotion Conference. Under the theme “Harmonious Hangzhou, Creating and Sharing the Future,” the event brought together entrepreneurs, investors, academics, and industry experts from both China and the United States to discuss future opportunities. The conference was jointly hosted by Hangzhou Talent Group Co., Ltd. and the Development Zone Innovation and Entrepreneurship Bureau, aiming to accelerate and attract startup projects by returnee talents, connect Jiangsu and Zhejiang enterprises seeking international expansion, identify collaboration opportunities in both markets, and promote technological innovation and ecosystem integration in the biomedicine field between the two countries.

On the morning of June 26, Dr. Jiasheng Song delivered a keynote speech titled “Decoding the Success of Hangzhou’s Quasi-Unicorn: The Journey of DIFF Biotech,” providing a brief introduction to the company’s multiple “First-in-Class” technological innovations since its establishment. DIFF Biotech continues to explore the application potential of recombinant virus technology, injecting new technical capabilities into areas such as mucosal immunity, antiviral drug discovery, gene therapy, and novel vaccine development.

The phased achievements of DIFF Biotech demonstrate the feasibility of returning to China to start a business after studying in the U.S. Adhering to the philosophy of “Making a Difference for the World,” the company drives its development with strong technological capabilities. We look forward to building a bridge of cooperation across the Pacific with enterprises, experts, investors, and stakeholders from both China and the U.S., striving to incubate forward-thinking international collaborative projects and pioneering an unbounded future along the path of open innovation.